Compass Pathways Plc CMPS

NAS: CMPS | ISIN: US20451W1018   31/05/2024
7,380 USD (-0,54%)
(-0,54%)   31/05/2024

8 mei 2024 · Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights · Persbericht

8 mei 2024 · Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder · Persbericht

2 mei 2024 · Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment · Persbericht

29 april 2024 · Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression · Persbericht

28 maart 2024 · Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors · Persbericht

29 februari 2024 · Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights  · Persbericht

16 januari 2024 · Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved · Persbericht

5 januari 2024 · Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement · Persbericht

19 december 2023 · Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder · Persbericht

7 december 2023 · Compass Pathways appoints Teri Loxam as Chief Financial Officer · Persbericht

6 december 2023 · Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry · Persbericht

15 november 2023 · Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center · Persbericht

2 november 2023 · COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights · Persbericht

26 oktober 2023 · COMPASS Pathways announces CFO transition · Persbericht

19 september 2023 · The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis · Persbericht

18 september 2023 · COMPASS Pathways appoints Daphne Karydas to its Board of Directors · Persbericht

6 september 2023 · COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression · Persbericht

16 augustus 2023 · COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors · Persbericht

3 augustus 2023 · COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights   · Persbericht

25 juli 2023 · First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine · Persbericht

Mijn selecties